334 related articles for article (PubMed ID: 20303741)
21. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
22. The role of the HGF/Met axis in mesothelioma.
Thayaparan T; Spicer JF; Maher J
Biochem Soc Trans; 2016 Apr; 44(2):363-70. PubMed ID: 27068941
[TBL] [Abstract][Full Text] [Related]
23. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
24. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
25. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Lancet Oncol; 2009 Jul; 10(7):709-17. PubMed ID: 19573800
[TBL] [Abstract][Full Text] [Related]
26. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
27. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
29. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
31. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
[TBL] [Abstract][Full Text] [Related]
32. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Wang X; Le P; Liang C; Chan J; Kiewlich D; Miller T; Harris D; Sun L; Rice A; Vasile S; Blake RA; Howlett AR; Patel N; McMahon G; Lipson KE
Mol Cancer Ther; 2003 Nov; 2(11):1085-92. PubMed ID: 14617781
[TBL] [Abstract][Full Text] [Related]
33. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).
To CT; Tsao MS
Oncol Rep; 1998; 5(5):1013-24. PubMed ID: 9683803
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.
Kim HJ
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630066
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
36. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
[TBL] [Abstract][Full Text] [Related]
37. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
38. Biomarker development in MET-targeted therapy.
Zhang Y; Du Z; Zhang M
Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1.
Seol DW; Chen Q; Zarnegar R
Oncogene; 2000 Feb; 19(9):1132-7. PubMed ID: 10713700
[TBL] [Abstract][Full Text] [Related]
40. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
